Vivos Inc. announced that they filed a patent application on their hydrogel component of IsoPet/RadioGel in the USA (16309: 17/943,311) and internationally (16389: PCT/US22/43274) under The Patent Cooperation Treaty (PCT). Over the last eighteen months team has worked with polymer contracting experts to optimize hydrogel component. the objectives were to maximize production output, to refine specifications to yield the optimum gelation and resorption characteristics, to demonstrate reproducibility and to ensure that any residual solvents were minor and well below the FDA specifications limits for human therapy.

As part of improved Quality Management System, are confident that the new Vivos Inc. Standard Operating Procedure for Polymer Production will meet GMP/FDA Specifications.